Novel deregulated genes in the etiology and progression of human prostate cancer

Project: Research project

Description

DESCRIPTION (provided by applicant): Prostate cancer (PC) is among the most commonly diagnosed malignancies and the second leading cause of cancer-related deaths in men. Although significant progress in the development of early detection tests has led to improved management of patients diagnosed with organ-confined PCs, the progression to locally invasive and metastatic hormone-refractory PCs (HRPCs) typically leads to treatment resistance, disease relapse and the death of patients. Therefore, a better understanding of etiological causes responsible for PC initiation and progression and treatment resistance is needed to identify novel molecular therapeutic targets. Recent lines of evidence have revealed that the malignant transformation of adult prostatic stem/progenitor cells into highly tumorigenic PC-initiating cells may provide critical functions in PC progression, metastases at distant tissues, treatment resistance and disease relapse. In considering these advances, the central hypothesis of this proposal is that the activation of specific oncogenic products induced in PC-initiating cells and their progenies during PC etiology and progression, including an up-regulation of EGFR and hedgehog signaling elements, may cooperate for their sustained growth, survival, invasion, metastases, treatment resistance and disease relapse. Based on this hypothesis, the long-term objective is to evaluate the potential benefit to simultaneously target EGFR and hedgehog cascades for eradicating PC- and metastasis-initiating cells and their progenies and improving the current clinical anti-androgenic treatments and docetaxel-based chemotherapies against locally invasive, androgen independent and metastatic PCs. For this, we will use in vitro and in vivo human PC cell models, and a large panel of patient's prostatic tissues relevant to prostate carcinogenesis. Three specific aims are proposed. AIM I will establish the specific functions and molecular mechanisms of EGFR and hedgehog pathways in the malignant transformation of PC stem/progenitor cells and their progenies during PC initiation and progression. AIM II will identify the drug resistance-associated molecules modulated through the activation of EGF-EGFR and sonic hedgehog cascades in PC stem/progenitor cells versus their progenies. AIM III will establish the therapeutic benefit of co-targeting EGFR and sonic hedgehog pathways for eradicating PC- and metastasis-initiating cells and their progenies and improving current clinical therapies. Altogether, these studies should delineate the specific functions provided by EGFR and hedgehog pathways in the acquisition of a more malignant phenotype and resistance of PC stem/progenitor cells and their progenies to current clinical therapies. The therapeutic interest of co-targeting EGFR and hedgehog cascades to eradicate the total PC cell mass and improve current anti-androgenic treatments and docetaxel-based chemotherapies for treating PC patients and thereby prevent disease relapse and the death of patients will be established. PUBLIC HEALTH RELEVANCE: The research program aims to establish the implications of EGFR and hedgehog cascades and other interacting pathways in the malignant transformation of PC stem/progenitor cells and their progenies and treatment resistance and validate novel therapeutic targets for improving current therapies and preventing disease relapse and the death of PC patients. The studies will consist to delineate the gene products modulated through the EGFR and hedgehog pathways that can cooperate in PC progression and treatment resistance and validate novel therapeutic targets for eradicating total PC cell mass by using human PC cell models and prostatic tissue specimens from patients relevant to prostate carcinogenesis.
StatusFinished
Effective start/end date5/1/102/29/16

Funding

  • National Institutes of Health: $358,242.00
  • National Institutes of Health: $336,747.00
  • National Institutes of Health: $358,242.00
  • National Institutes of Health: $37,614.00
  • National Institutes of Health: $369,322.00
  • National Institutes of Health: $44,583.00
  • National Institutes of Health: $347,495.00
  • National Institutes of Health: $9,522.00

Fingerprint

Prostatic Neoplasms
Genes
docetaxel
Neoplasm Metastasis
Therapeutics
Stem Cells
Recurrence
Disease Resistance
Second Primary Neoplasms
Drug Resistance
Epidermal Growth Factor
Androgens
Up-Regulation
Neoplastic Stem Cells
Drug Therapy
Hormones
Phenotype
Survival

ASJC

  • Medicine(all)